Type your tag names separated by a space and hit enter




Trade Name(s)

  • Avycaz

Ther. Class.

Pharm. Class.
third generation cephalosporins
beta lactamase inhibitors


  • Complicated intra-abdominal infections (in combination with metronidazole).
  • Complicated urinary tract infections (cUTIs).


  • Ceftazidime– Binds to the bacterial cell wall membrane, causing cell death.
  • Avibactam– Inhibits beta-lactamase, an enzyme that destroys penicillins and cephalosporins.

Therapeutic Effect(s):

Death of susceptible bacteria with resolution of infection.


Active against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, Pseudomonas aeruginosa, Citrobacter koserii, Enterobacter aerogenes, Citrobacter freundii, and Proteus spp.


Absorption: IV administration results in complete bioavailability.

Distribution: Ceftazidime– Widely distributed, enters breast milk in low concentrations; avibactam– widely distributed

Metabolism and Excretion: ceftazidime– minimally metabolized, 80–90% excreted unchanged in urine; avibactam– minimally metabolized, mainly excreted unchanged in urine.

Half-life: Ceftazidime– 2.8–3.3 hr (↑ in renal impairment); avibactam– 2.2–2.7 hr.

TIME/ACTION PROFILE (blood levels)

IVrapidend of infusion8 hr (↑ in renal impairment)


Contraindicated in:

  • Known hypersensitivity to ceftazidime, other cephalosporins or avibactam-containing products; cross-sensitivity with other penicillins, carbapenems, and cephalosporins may occur.

Use Cautiously in:

  • CCr 30–50 mL/min (efficacy may be ↓, monitor renal function frequently and adjust dose if necessary);
  • Geri: Consider age-related impairment of renal function;
  • OB: Use during pregnancy only if clearly needed
  • Lactation:Use cautiously in breast-feeding women;
  • Pedi: Safety and effectiveness not established.

Adverse Reactions/Side Effects

CNS: SEIZURES (↑ IN RENAL IMPAIRMENT), anxiety, dizziness, headache


F and E: hypokalemia

Hemat: eosinophilia, thrombocytopenia

Misc: hypersensitivity reactions including anaphylaxis and serious skin reactions

* CAPITALS indicate life-threatening.
Underline indicate most frequent.



Probenecid may ↓ renal excretion of avibactam; concurrent administration is not recommended.


IV: (Adults CCr >50 mL/min): 2.5 g (2 g ceftazidime/0.5 g avibactam) every 8 hr.

Renal Impairment
(Adults) CCr 31–50 mL/min– 1.25 g (1 g ceftazidime/ 0.25 g avibactam) every 8 hr; CCr 16–30 mL/min– 0.94 g (0.75 g ceftazidime/0.19 g avibactam) every 12 hr; CCr 6–15 mL/min– 0.94 g (0.75 g ceftazidime/0.19 g avibactam) every 24 hr; CCr 6–15 mL/min– 0.94 g (0.75 g ceftazidime/0.19 g avibactam) every 48 hr: hemodialysis– Administer dose after or on day of hemodialysis.


Powder for IV injection: ceftazidime 2 g/avibactam 0.5 g/vial


  • Assess for infection (vital signs; appearance of wound, sputum, urine, and stool; WBC) at beginning of and throughout therapy
  • Before initiating therapy, obtain a history to determine previous use of and reactions to penicillins, cephalosporins or carbapenems. Persons with a negative history of sensitivity may still have an allergic response.
  • Obtain specimens for culture and sensitivity before initiating therapy. First dose may be given before receiving results.
  • Observe patient for signs and symptoms of anaphylaxis (rash, pruritus, laryngeal edema, wheezing). Discontinue the drug and notify health care professional immediately if these symptoms occur. Keep epinephrine, an antihistamine, and resuscitation equipment close by in the event of an anaphylactic reaction
  • Monitor bowel function. Diarrhea, abdominal cramping, fever, and bloody stools should be reported to health care professional promptly as a sign of CDAD. May begin up to several mo following cessation of therapy
  • Monitor for signs and symptoms of encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, coma), myoclonus, and seizures during and following therapy. May require immediate treatment, dose adjustment, or discontinuation of therapy.

Lab Test Considerations: May cause seroconversion from a negative to a positive direct Coombs' test. If anemia develops during or after therapy, perform a direct Coombs' test.

  • May cause a false-positive reaction for glucose in urine with certain methods; use enzymatic glucose oxidase reactions.

Potential Diagnoses


  • Reconstitute with 10 mL of Sterile Water for injection. 0.9% NaCl, D5W, D5/0.9% NaCl, D5/0.45% NaCl, D2.5/0.9% NaCl, D2.5/0.45% NaCl, or LR. Mix gently. Diluent: Use same diluent used for reconstitution for a volume between 50 mL and 250 mL.Concentration:40 and 10 mg/mL of ceftazidime and avibactam, respectively to 8 and 2 mg/mL of ceftazidime and avibactam, respectively. Solution ranges from clear to light yellow; do not administer solutions that are discolored or contain particulate matter. Solution is stable for 12 hrs at room temperature or 24 hrs if refrigerated.
  • Rate: Infuse over 2 hrs.

Patient/Family Teaching

  • Explain the purpose of ceftazidime/avibactam to patient.
  • Instruct patient to notify health care professional if fever and diarrhea develop, especially if stool contains blood, pus, or mucus. Advise patient not to treat diarrhea without consulting health care professional.
  • Advise patient to notify health care professional immediately if signs and symptoms of allergic reactions or nervous system reactions occur.
  • Advise female patient to notify health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

Resolution of the signs and symptoms of infection. Length of time for complete resolution depends on the organism and site of infection.

ceftazidime/avibactam is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Medicine Central™ is a quick-consult mobile and web resource that includes diagnosis, treatment, medications, and follow-up information on over 700 diseases and disorders, providing fast answers—anytime, anywhere. Learn more.


Quiring, Courtney, et al. "Ceftazidime/avibactam." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110352/all/ceftazidime_avibactam.
Quiring C, Sanoski CA, Vallerand AH. Ceftazidime/avibactam. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110352/all/ceftazidime_avibactam. Accessed April 21, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Ceftazidime/avibactam. In Davis's Drug Guide. Available from https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110352/all/ceftazidime_avibactam
Quiring C, Sanoski CA, Vallerand AH. Ceftazidime/avibactam [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 21]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110352/all/ceftazidime_avibactam.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - ceftazidime/avibactam ID - 110352 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/110352/all/ceftazidime_avibactam PB - F.A. Davis Company ET - 16 DB - Medicine Central DP - Unbound Medicine ER -